Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biocon Ltd.
DescriptionHumanized mAb that binds CD20
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation
PartnerVaccinex Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today